Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8691847 | PORTOLA PHARMS INC | Benzamides and related inhibitors of factor Xa |
Sep, 2020
(3 years ago) | |
US6376515 | PORTOLA PHARMS INC | Benzamides and related inhibitors of factor Xa |
Sep, 2020
(3 years ago) | |
US8518977 | PORTOLA PHARMS INC | Benzamides and related inhibitors of factor XA |
Sep, 2020
(3 years ago) | |
US6835739 | PORTOLA PHARMS INC | Benzamides and related inhibitors of factor Xa |
Sep, 2020
(3 years ago) | |
US7598276 | PORTOLA PHARMS INC | Pharmaceutical salts and polymorphs of a factor Xa inhibitor |
Nov, 2026
(2 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9629831 | PORTOLA PHARMS INC | Benzamides and related inhibitors of factor XA |
Sep, 2020
(3 years ago) | |
US9555023 | PORTOLA PHARMS INC | Pharmaceutical salts and polymorphs of a factor Xa inhibitor |
Nov, 2026
(2 years from now) | |
US8557852 | PORTOLA PHARMS INC | Methods of using crystalline forms of a salt of a factor Xa inhibitor |
Sep, 2028
(4 years from now) | |
US8987463 | PORTOLA PHARMS INC | Methods of synthesizing factor Xa inhibitors |
Dec, 2030
(6 years from now) | |
US8404724 | PORTOLA PHARMS INC | Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor |
Mar, 2031
(6 years from now) |
Bevyxxa is owned by Portola Pharms Inc.
Bevyxxa contains Betrixaban.
Bevyxxa has a total of 10 drug patents out of which 5 drug patents have expired.
Expired drug patents of Bevyxxa are:
Bevyxxa was authorised for market use on 23 June, 2017.
Bevyxxa is available in capsule;oral dosage forms.
Bevyxxa can be used as prophylaxis of venous thromboembolism, prophylaxis of venous thrombosis, inhibiting coagulation, prophylaxis of pulmonary embolism, preventing condition characterized by undesired thrombosis.
Drug patent challenges can be filed against Bevyxxa from 23 June, 2021.
The generics of Bevyxxa are possible to be released after 29 March, 2031.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 23, 2022 |
Drugs and Companies using BETRIXABAN ingredient
NCE-1 date: 23 June, 2021
Market Authorisation Date: 23 June, 2017
Treatment: Prophylaxis of venous thromboembolism; Prophylaxis of pulmonary embolism; Prophylaxis of venous thrombosis; Inhibiting coagulation; Preventing condition characterized by undesired thrombosis
Dosage: CAPSULE;ORAL